Formosa has signed an exclusive licensing agreement with Medvisis for APP13007 for post-operative inflammation and pain after ...

This latest update comes after Advanz secured a suspension of the European Commission’s original revocation in September 2024 ...

There are currently no FDA- or EMA-approved treatment options available for any form of frontotemporal dementia.

The US Food and Drug Administration has declined to approve Applied Therapeutics’ govorestat for classic galactosemia.

Trump's controversial administration nominees signal global ramifications for drug regulation, health funding and pharmaceutical investment.